ES2165434T3 - Virus atenuado de vacunacion y transferencia de genes, procedimiento de preparacion del virus y composiciones farmaceuticas que contienen el mismo. - Google Patents

Virus atenuado de vacunacion y transferencia de genes, procedimiento de preparacion del virus y composiciones farmaceuticas que contienen el mismo.

Info

Publication number
ES2165434T3
ES2165434T3 ES95933386T ES95933386T ES2165434T3 ES 2165434 T3 ES2165434 T3 ES 2165434T3 ES 95933386 T ES95933386 T ES 95933386T ES 95933386 T ES95933386 T ES 95933386T ES 2165434 T3 ES2165434 T3 ES 2165434T3
Authority
ES
Spain
Prior art keywords
virus
vrna
viral
promoter
progeny
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95933386T
Other languages
English (en)
Inventor
Gerd Hobom
Gabriele Neumann
Annette Menke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HOBOM GERD PROF DR DR
Original Assignee
HOBOM GERD PROF DR DR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HOBOM GERD PROF DR DR filed Critical HOBOM GERD PROF DR DR
Application granted granted Critical
Publication of ES2165434T3 publication Critical patent/ES2165434T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

LA TRANSCRIPCION POR ARN POLIMERASA I IN VIVO EN CELULAS TRANSFECTADAS TRANSITORIAMENTE CON ADN, SE HA UTILIZADO PARA LA EXPRESION DE MOLECULAS DE VARN INFLUENZA, QUE CODIFICAN PARA ACETILTRANSFERASA DE CLORANFENICOL (CAT) EN ORIENTACION ANTISENTIDO. LA SUPERINFECCION CON VIRUS INFLUENZA SIRVIO PARA PROPORCIONAR ARN POLIMERASA VIRAL, Y OTRAS PROTEINAS, PARA LA CONVERSION TRANSCRIPCIONAL DE UNA HEBRA NEGATIVA DE VARN, EN MOLECULAS DE MARN DE HEBRA POSITIVA, QUE EXPRESAN UNA ACTIVIDAD CAT. DICHO SISTEMA SE HA UTILIZADO PARA UN ANALISIS VIA INTERCAMBIO DE NUCLEOTIDOS, ASI COMO DE VIA DELECIONES E INSERCIONES, DE AMBOS SEGMENTOS TERMINALES DE LA SECUENCIA VARN, QUE CONSTITUYEN COOPERATIVAMENTE LA ESTRUCTURA DEL PROMOTOR DE VARN. SE HAN OBTENIDO VARIOS MUTANTES QUE MEJORAN CONSIDERABLEMENTE LOS NIVELES DE EXPRESION SOBRE LOS NIVELES DE LOS TIPOS SILVESTRES, QUE SE PUEDEN TAMBIEN EMPAQUETAR Y TRANSMITIR SUCESIVAMENTE A LOS VIRUS DE LA PROGENIE. LOS DATOS OBTENIDOS PARA DICHAS MUTACIONES EN VARIOSELEMENTOS PROMOTORES, APOYAN UN MODELO DE ESTRUCTURAS PROMOTORAS CONSECUTIVAS DE VARN DE DOBLE HEBRA, RELACIONADAS CON LA ARN POLIMERASA VIRAL, Y CON LA INICIACION DE LA SINTESIS DE ARN. PREPARACIONES DE VIRUS INFLUENZA ATENUADOS, DESTINADOS A VACUNACION, INCLUYEN UN SOLO SEGMENTO RECOMBINANTE CON MUTACION(ES) FAVORECEDORA(S) DEL PROMOTOR, QUE DETERMINAN LA SOBREEXPRESION DE UN PRODUCTO GENICO PROPIO O EXTRAÑO, QUE AL MISMO TIEMPO SIRVE, DEBIDO A SU SOBREEXPRESION, PARA DISMINUIR EL NUMERO DE SEGMENTOS DE RIBONUCLEOPROTEINA (RNP) DEL VIRUS AUXILIAR. LOS MISMOS VIRUS, SE SOMETIERON ADEMAS A UNA ETAPA DE RUPTURA CON RIBOZIMA EN UNO DE LOS SEGMENTOS VIRALES AUXILIARES, LA CUAL ELIMINA DICHA FUNCION VITAL Y DICHA ESTRUCTURA DE LOS VIRUS DE LA PROGENIE, A UNA TASA ELEVADA. LOS VIRUS ATENUADOS RESULTANTES, INTERACCIONAN CON SUS CELULAS DIANA SOLO EN UN CICLO DE INFECCION ABORTIVA, Y SON INCAPACES DE PRODUCIR PROGENIE VIRAL.
ES95933386T 1994-09-30 1995-09-18 Virus atenuado de vacunacion y transferencia de genes, procedimiento de preparacion del virus y composiciones farmaceuticas que contienen el mismo. Expired - Lifetime ES2165434T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94115505A EP0704533A1 (en) 1994-09-30 1994-09-30 An attenuated vaccination virus, a method to make the virus and a pharmaceutical compositions comprising the virus

Publications (1)

Publication Number Publication Date
ES2165434T3 true ES2165434T3 (es) 2002-03-16

Family

ID=8216345

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95933386T Expired - Lifetime ES2165434T3 (es) 1994-09-30 1995-09-18 Virus atenuado de vacunacion y transferencia de genes, procedimiento de preparacion del virus y composiciones farmaceuticas que contienen el mismo.

Country Status (10)

Country Link
US (1) US6524588B1 (es)
EP (3) EP0704533A1 (es)
JP (1) JP2000509962A (es)
AT (1) ATE210727T1 (es)
AU (1) AU3607695A (es)
DE (1) DE69524618T2 (es)
ES (1) ES2165434T3 (es)
FI (1) FI971272A (es)
NZ (1) NZ293600A (es)
WO (1) WO1996010641A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9809666D0 (en) * 1998-05-06 1998-07-01 Isis Innovation Modified viruses
EP1035209A1 (en) * 1999-03-06 2000-09-13 ARTEMIS Pharmaceuticals GmbH Stable recombinant influenza viruses free of helper viruses
PT1185615E (pt) * 1999-04-06 2007-10-04 Wisconsin Alumni Res Found ''vírus da influenza recombinantes para vacinas e tratamento genético''
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
EP1201760A1 (en) * 2000-10-30 2002-05-02 ARTEMIS Pharmaceuticals GmbH Influenza virus vector for human dendritic cells
US20030099670A1 (en) * 2001-02-09 2003-05-29 Gert Hobom Influenza viruses with enhanced transcriptional and replicational capacities
JP2008520248A (ja) 2004-11-19 2008-06-19 ウィスコンシン・アラムナイ・リサーチ・ファウンデイション タンデム転写ユニットを有する組換えインフルエンザベクター
US20100055672A1 (en) * 2006-05-11 2010-03-04 Geneohm Sciences, Inc. 100% sequence identity detection methods for variable genomes
WO2009100285A1 (en) * 2008-02-08 2009-08-13 Colgate-Palmolive Company Oral care toothbrush
CA2706505C (en) * 2008-02-08 2014-11-18 Colgate-Palmolive Company Effervescent compositions
US20110044914A1 (en) * 2008-02-08 2011-02-24 Colgate -Palmolive Company Cleaning compositions and methods
AR070592A1 (es) * 2008-02-08 2010-04-21 Colgate Palmolive Co Composiciones para el blanqueamiento dental
CN101938970A (zh) * 2008-02-08 2011-01-05 高露洁-棕榄公司 牙齿密封剂
BRPI0906462A2 (pt) * 2008-02-08 2015-07-14 Colgate Palmolive Co Método para tratar, melhorar, inibir ou evitar boca seca, saliva artificial, uso de um aminoácido básico em forma livre ou de sal, e, aminoácido básico em forma livre ou de sal
CA2706512C (en) * 2008-02-08 2013-12-24 Colgate-Palmolive Company Compositions and devices
CN101938987A (zh) * 2008-02-08 2011-01-05 高露洁-棕榄公司 口腔护理制品及其应用与制备方法
BRPI0906464A2 (pt) 2008-02-08 2015-07-14 Colgate Palmolive Co Fio dental, embalagem para armazenar ou dispensar fio dental, e, métodos para produzir fio dental e para tratar um condição
AU2009212335B2 (en) * 2008-02-08 2011-12-01 Colgate-Palmolive Company Compositions comprising basic amino acid and soluble carbonate salt
US20100330002A1 (en) * 2008-02-08 2010-12-30 Colgate-Palmolive Company Compositions and methods comprising basic amino acid peptides and proteases
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
US9315464B1 (en) 2013-01-31 2016-04-19 Nant Holdings Ip, Llc Small molecule inhibitors of influenza A RNA-dependent RNA polymerase
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
CN104593330A (zh) * 2015-01-19 2015-05-06 中国科学院微生物研究所 含有a型流感特异性启动子的重组293t细胞及其应用
CN113874496A (zh) 2019-02-08 2021-12-31 威斯康星校友研究基金会(Warf) 人源化细胞系
WO2021041624A2 (en) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Recombinant influenza viruses with stabilized ha for replication in eggs

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166057A (en) * 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US5690937A (en) * 1995-06-05 1997-11-25 Aviron Temperature sensitive clustered changed-to-alanine mutants of influenza virus PB2 gene

Also Published As

Publication number Publication date
WO1996010641A1 (en) 1996-04-11
EP0704533A1 (en) 1996-04-03
US6524588B1 (en) 2003-02-25
ATE210727T1 (de) 2001-12-15
JP2000509962A (ja) 2000-08-08
EP1091000A1 (en) 2001-04-11
FI971272A (fi) 1997-05-26
EP0783586B1 (en) 2001-12-12
FI971272A0 (fi) 1997-03-26
AU3607695A (en) 1996-04-26
EP0783586A1 (en) 1997-07-16
NZ293600A (en) 1999-01-28
DE69524618T2 (de) 2002-08-14
DE69524618D1 (de) 2002-01-24

Similar Documents

Publication Publication Date Title
ES2165434T3 (es) Virus atenuado de vacunacion y transferencia de genes, procedimiento de preparacion del virus y composiciones farmaceuticas que contienen el mismo.
Berkner et al. Generation of adenovirus by transfection of plasmids
EP1035209A1 (en) Stable recombinant influenza viruses free of helper viruses
CA2229631C (en) Gene therapy using ovine adenoviral vectors
CN109689865A (zh) Bcl11a归巢核酸内切酶变体、组合物和使用方法
Le Nouën et al. Attenuation of human respiratory viruses by synonymous genome recoding
WO1995006743A3 (en) Methods and compositions for the large scale production of recombinant adeno-associated virus
HUP9900050A1 (hu) Rekombináns adenovírusok, és felhasználásuk adeno-asszociált vírusok (AAV) előállítására, komplementáló sejtvonalak, és az illető adenovírusokat tartalmazó gyógyszerkészítmények
Flick et al. Mutational analysis of the Uukuniemi virus (Bunyaviridae family) promoter reveals two elements of functional importance
Ohuchi et al. Human influenza virus hemagglutinin with high sensitivity to proteolytic activation
JP2002536978A5 (es)
Flick et al. Functional analysis of the noncoding regions of the Uukuniemi virus (Bunyaviridae) RNA segments
ES2300105T3 (es) Vectores adenoviricos para terapia genica.
CN103215308A (zh) 表达重组人fviii的整合质粒、细胞株及其构建方法和应用
Bergmann et al. Mutations in the nonconserved noncoding sequences of the influenza A virus segments affect viral vRNA formation
HUP0101355A2 (hu) Fehérjetermelésre és célba juttatására szolgáló genomi szekvenciák
US20230310555A1 (en) Compositions for genome editing and methods of use thereof
KR880014108A (ko) 동물 세포내의 폴리펩타이드에 대한 유전자를 가진 분리된 DNA 조각의 발현을 위한 에피조말 벡터(episomal vector)와 그 제조방법
WO2000049166A3 (en) Production of helper dependent adenovirus vectors based on use of endonucleases
WO2002008434A3 (en) Bicistronic influenza comprising two genes in tandem
US7034142B1 (en) Method to improve translation of polypeptides by using untranslated regions from heat-shock proteins
CN100365119C (zh) 抗hiv病毒的多肽及其编码基因与应用
HUP0102517A2 (hu) INFA2 kódoló régiójától 5' -irányban található genomi eredetű szekvenciák, alkalmazásuk INFA2-bevitelre alkalmas gyógyszerek előállítására, valamint eljárások INFA2 előállítására
CN111471696A (zh) 一种构建d型流感病毒反向遗传操作系统的方法及其应用
CN117431233A (zh) 一种超小型rna碱基编辑器及其应用

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 783586

Country of ref document: ES